To address limitations with CAR T therapies targeting CD19, Allogene Therapeutics Inc. has developed ALLO-329, a CD19/CD70-targeting CAR therapy that is able to deplete activated alloreactive ...
A disrupted balance between T-effector and T-regulatory cells, together with the activation of autoreactive or alloreactive B cells that generate pathogenic antibodies, is a defining feature of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results